Mesenchymal stem cells modifications for enhanced bone targeting and bone regeneration.

Mesenchymal stem cells modifications for enhanced bone targeting and bone regeneration. Regen Med. 2020 Apr 16;: Authors: Safarova Y, Umbayev B, Hortelano G, Askarova S Abstract In pathological bone conditions (e.g., osteoporotic fractures or critical size bone defects), increasing the pool of osteoblast progenitor cells is a promising therapeutic approach to facilitate bone healing. Since mesenchymal stem cells (MSCs) give rise to the osteogenic lineage, a number of clinical trials investigated the potential of MSCs transplantation for bone regeneration. However, the engraftment of transplanted cells is often hindered by insufficient oxygen and nutrients supply and the tendency of MSCs to home to different sites of the body. In this review, we discuss various approaches of MSCs transplantation for bone regeneration including scaffold and hydrogel constructs, genetic modifications and surface engineering of the cell membrane aimed to improve homing and increase cell viability, proliferation and differentiation. PMID: 32297546 [PubMed - as supplied by publisher]
Source: Regenerative Medicine - Category: Genetics & Stem Cells Authors: Tags: Regen Med Source Type: research

Related Links:

Conditions:   Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorders;   Chronic Myeloid Leukemia;   Myelofibrosis;   Multiple Myeloma;   Malignant Lymphoma Interventions:   Drug: MDG1021 dose 1;   Drug: MDG1021 dose 2;   Drug: MDG1021 dose 3;   Drug: MDG1021 optimal dose Sponsor:   Medigene AG Recruiting
Source: - Category: Research Source Type: clinical trials
A sizable portion of the variable efficacy of first generation stem cell therapies as presently practiced may be due to a poor quality of cells following expansion in culture. Regardless of quality, near all such cells die shortly after transplantation. Few clinics and few approaches to cell therapy lead to lasting survival and engraftment of transplanted cells, and beneficial effects are largely mediated by the short period of signaling produced by these cells. A range of approaches have been taken in attempts to make transplanted cells more robust: methodological improvements in the process of obtaining and culturing cel...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Severe combined immunodeficiency (SCID) and other T cell lymphopenias can be detected during newborn screening (NBS) by measuring T cell receptor excision circles (TRECs) in dried blood spot (DBS) DNA. Second tier next generation sequencing (NGS) with an amplicon based targeted gene panel using the same DBS DNA was introduced as part of our prospective pilot research project in 2015. With written parental consent, 21 000 newborns were TREC-tested in the pilot. Three newborns were identified with SCID, and disease-causing variants in IL2RG, RAG2, and RMRP were confirmed by NGS on the initial DBS DNA. The molecular findings ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractPurpose of ReviewThe most serious DNA damage, DNA double strand breaks (DNA-dsb), leads to mutagenesis, carcinogenesis or apoptosis if left unrepaired. Non-homologous end joining (NHEJ) is the principle repair pathway employed by mammalian cells to repair DNA-dsb. Several proteins are involved in this pathway, defects in which can lead to human disease. This review updates on the most recent information available for the specific diseases associated with the pathway.Recent FindingsA new member of the NHEJ pathway, PAXX, has been identified, although no human disease has been associated with it. The clinical phenoty...
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research
Busulfan (1,4-butanediol dimethanesulfonate) is a bifunctional alkylating agent that is cytotoxic to hematopoietic stem and progenitor cells (HSPC).1 Busulfan (BU) is widely used for cytoreduction (full or partial) in both myeloablative and reduced intensity allogeneic hematopoietic stem cell transplant (HSCT) conditioning regimens and prior to autologous gene therapy (GT). Appropriate BU dosing is critical to the success of HSCT, because low BU plasma exposure can result in engraftment failure and high BU exposure can increase regimen-related toxicity.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Primary immunodeficiency diseases (PID) are a heterogeneous group of monogenic disorders (majority) affecting the immune system. To date, more than 430 different genes causing PID are identified.1 Since the first report in 1968 showing that allogeneic hematopoietic cell transplantation (HCT) could correct the immune function of a patient with severe combined immunodeficiency (SCID)2, it has become the treatment of choice for a significant number of PIDs. An HLA identical sibling is considered the ideal donor for HCT, but less than 25% of patients will have an available unaffected matched sibling donor (MSD).
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Chronic lymphocytic leukemia (CLL) is generally considered an indolent disease of the elderly, but more aggressive subtypes have been identified based on clinical and biological features1. In particular, patients who are refractory or early relapsing (R/R) after chemoimmunotherapy (CIT) and patients carrying 17p deletion (del17p) and/or p53 mutation (TP53mut) have shown poor survival ranging between 12 and 24 months after CIT2. For these reasons, young patients have been conventionally considered good candidates for allogeneic stem cell transplantation (alloSCT), with the first recommendations formally defined in 2007 by t...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Preliminary research on the effects and mechanisms of umbilical cord‑derived mesenchymal stem cells in streptozotocin‑induced diabetic retinopathy. Int J Mol Med. 2020 Aug;46(2):849-858 Authors: Zhao K, Liu J, Dong G, Xia H, Wang P, Xiao X, Chen Z Abstract Diabetic retinopathy (DR) is one of the most prevalent microvascular complications of diabetes, and a common cause of blindness in working‑age individuals. Mesenchymal stem cell (MSC) transplantation has been considered a promising intervention therapy for DR, wherein the differentiation of MSCs into nerve cells plays an essential role. Howeve...
Source: International Journal of Molecular Medicine - Category: Molecular Biology Authors: Tags: Int J Mol Med Source Type: research
Publication date: Available online 7 July 2020Source: The Lancet HIVAuthor(s): Annemarie M J Wensing, Christian Chabannon, Jurgen Kuball
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research
In this study, sex chromosome analysis was performed in patients with oral squamous cell carcinoma (OSCC) that developed after hematopoietic stem cell transplantation from the opposite gender to examine whether OSCC originates from bone marrow (BM) stem cells. Gene expression patterns in patients with possible BM stem cell-derived OSCC were compared with those in patients with normally developed OSCC.We used microarray analysis to examine whether OSCC with a possible BM origin shows specific pattern of the gene expression.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
More News: Clinical Trials | Genetics | Nutrition | Orthopaedics | Stem Cell Therapy | Stem Cells | Transplants